Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SRI 37892 is a Fzd7 inhibitor with potent activities against Wnt/β-catenin signaling and cancer cell viability.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 397.00 | |
5 mg | In stock | $ 970.00 | |
10 mg | In stock | $ 1,290.00 | |
25 mg | In stock | $ 1,950.00 | |
50 mg | In stock | $ 2,620.00 | |
100 mg | In stock | $ 3,530.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 1,130.00 |
Description | SRI 37892 is a Fzd7 inhibitor with potent activities against Wnt/β-catenin signaling and cancer cell viability. |
In vitro | SRI37892 block Wnt/β-catenin signaling in HEK293 cells induced by Wnt3A and LRP6 with IC50 of 0.66 μM and 0.78 μM, respectively[1]. |
Molecular Weight | 465.53 |
Formula | C26H19N5O2S |
CAS No. | 1030769-75-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (107.4 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SRI 37892 1030769-75-5 Cytoskeletal Signaling Stem Cells Wnt/beta-catenin SRI37892 SRI-37892 inhibitor inhibit